NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

NCT06693908

Active Not RecruitingPhase 1, Phase 2

Sponsor: Genentech, Inc.

Conditions: Moderate to Severe Ulcerative Colitis

Interventions: Vixarelimab

Countries: Germany

This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Diagnosis of UC established at least 3 months
* Moderately to severely active UC
* Participants must meet criteria for either advanced therapy failure or conventional therapy failure

Exclusion Criteria:

* Diagnosis of Crohn's disease or indeterminate colitis
* Suspicion of ischemic colitis, radiation colitis, microscopic colitis or infectious colitis
* Prior colectomy
* Prior treatment with systemic janus kinase (JAK) inhibitors

Locations (1)

Berlin, Germany